Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma

A 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2024-06, Vol.49 (6), p.584
Main Authors: Pretet, Valentin, Giraudet, Anne Laure, Vergnaud, Laure, Paquet, Emilie, Kryza, David
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 6
container_start_page 584
container_title Clinical nuclear medicine
container_volume 49
creator Pretet, Valentin
Giraudet, Anne Laure
Vergnaud, Laure
Paquet, Emilie
Kryza, David
description A 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.ABSTRACTA 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.
doi_str_mv 10.1097/RLU.0000000000005212
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_3041232272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3041232272</sourcerecordid><originalsourceid>FETCH-LOGICAL-p103t-761f4d4787c4235a987e4ebc811f0ac8628c773a08934f2bad12d80701aedc303</originalsourceid><addsrcrecordid>eNpNjkFLwzAYhoMoOKf_wEOOXjq_L0mb9DiKOqFimRsex7c0ZZGurU168N-LzMPey_vACw8vY_cIC4RcP67L7QLOkgoUF2yGqcwSECK_PONrdhPCFwBmmKkZq9ZU-76bbOtrxzcHN9Lwwz99PHDUmpdTUn28LbnvOPGKonddPK0rN1DsrWvbqaWRFzRa3_VHumVXDbXB3f33nG2fnzbFKinfX16LZZkMCDImOsNG1UobbZWQKeVGO-X21iA2QNZkwlitJYHJpWrEnmoUtQENSK62EuScPZy8w9h_Ty7E3dGHvzvUuX4KOwkKhRRCC_kL0VJR0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3041232272</pqid></control><display><type>article</type><title>Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><creator>Pretet, Valentin ; Giraudet, Anne Laure ; Vergnaud, Laure ; Paquet, Emilie ; Kryza, David</creator><creatorcontrib>Pretet, Valentin ; Giraudet, Anne Laure ; Vergnaud, Laure ; Paquet, Emilie ; Kryza, David</creatorcontrib><description>A 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.ABSTRACTA 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.</description><identifier>ISSN: 1536-0229</identifier><identifier>EISSN: 1536-0229</identifier><identifier>DOI: 10.1097/RLU.0000000000005212</identifier><language>eng</language><ispartof>Clinical nuclear medicine, 2024-06, Vol.49 (6), p.584</ispartof><rights>Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Pretet, Valentin</creatorcontrib><creatorcontrib>Giraudet, Anne Laure</creatorcontrib><creatorcontrib>Vergnaud, Laure</creatorcontrib><creatorcontrib>Paquet, Emilie</creatorcontrib><creatorcontrib>Kryza, David</creatorcontrib><title>Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma</title><title>Clinical nuclear medicine</title><description>A 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.ABSTRACTA 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.</description><issn>1536-0229</issn><issn>1536-0229</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNjkFLwzAYhoMoOKf_wEOOXjq_L0mb9DiKOqFimRsex7c0ZZGurU168N-LzMPey_vACw8vY_cIC4RcP67L7QLOkgoUF2yGqcwSECK_PONrdhPCFwBmmKkZq9ZU-76bbOtrxzcHN9Lwwz99PHDUmpdTUn28LbnvOPGKonddPK0rN1DsrWvbqaWRFzRa3_VHumVXDbXB3f33nG2fnzbFKinfX16LZZkMCDImOsNG1UobbZWQKeVGO-X21iA2QNZkwlitJYHJpWrEnmoUtQENSK62EuScPZy8w9h_Ty7E3dGHvzvUuX4KOwkKhRRCC_kL0VJR0Q</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Pretet, Valentin</creator><creator>Giraudet, Anne Laure</creator><creator>Vergnaud, Laure</creator><creator>Paquet, Emilie</creator><creator>Kryza, David</creator><scope>7X8</scope></search><sort><creationdate>20240601</creationdate><title>Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma</title><author>Pretet, Valentin ; Giraudet, Anne Laure ; Vergnaud, Laure ; Paquet, Emilie ; Kryza, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p103t-761f4d4787c4235a987e4ebc811f0ac8628c773a08934f2bad12d80701aedc303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pretet, Valentin</creatorcontrib><creatorcontrib>Giraudet, Anne Laure</creatorcontrib><creatorcontrib>Vergnaud, Laure</creatorcontrib><creatorcontrib>Paquet, Emilie</creatorcontrib><creatorcontrib>Kryza, David</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Clinical nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pretet, Valentin</au><au>Giraudet, Anne Laure</au><au>Vergnaud, Laure</au><au>Paquet, Emilie</au><au>Kryza, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma</atitle><jtitle>Clinical nuclear medicine</jtitle><date>2024-06-01</date><risdate>2024</risdate><volume>49</volume><issue>6</issue><spage>584</spage><pages>584-</pages><issn>1536-0229</issn><eissn>1536-0229</eissn><abstract>A 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.ABSTRACTA 69-year-old man diagnosed with progressive bone metastatic castration-resistant prostate adenocarcinoma and concurrent alcoholic cirrhosis with multiple hepatocellular carcinoma (HCC) nodules was referred to our nuclear medicine service for 177 Lu-PSMA-617 therapy. The patient's pretreatment screening using 68 Ga-PSMA-11 PET/CT revealed high prostate-specific membrane antigen expression in both prostatic and HCC lesions. The patient underwent 2 doses of 177 Lu-PSMA-617. Subsequent imaging assessments with 68 Ga-PSMA-11 PET/CT and hepatic MRI indicated progressive HCC nodules, while showing a partial response in prostatic bone metastases. Positive clinical and biological responses were observed only in prostatic disease, but not in HCC nodules.</abstract><doi>10.1097/RLU.0000000000005212</doi></addata></record>
fulltext fulltext
identifier ISSN: 1536-0229
ispartof Clinical nuclear medicine, 2024-06, Vol.49 (6), p.584
issn 1536-0229
1536-0229
language eng
recordid cdi_proquest_miscellaneous_3041232272
source HEAL-Link subscriptions: Lippincott Williams & Wilkins
title Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A04%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radionuclide%20Therapy%20With%20177%20Lu-PSMA%20in%20a%20Patient%20With%20Hepatocellular%20Carcinoma&rft.jtitle=Clinical%20nuclear%20medicine&rft.au=Pretet,%20Valentin&rft.date=2024-06-01&rft.volume=49&rft.issue=6&rft.spage=584&rft.pages=584-&rft.issn=1536-0229&rft.eissn=1536-0229&rft_id=info:doi/10.1097/RLU.0000000000005212&rft_dat=%3Cproquest%3E3041232272%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p103t-761f4d4787c4235a987e4ebc811f0ac8628c773a08934f2bad12d80701aedc303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3041232272&rft_id=info:pmid/&rfr_iscdi=true